UBS Initiates Coverage On Kura Oncology with Buy Rating, Announces Price Target of $27
Portfolio Pulse from Benzinga Newsdesk
UBS has initiated coverage on Kura Oncology with a Buy rating and set a price target of $27.
October 24, 2024 | 11:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has initiated coverage on Kura Oncology with a Buy rating and a price target of $27, indicating a positive outlook for the stock.
The initiation of coverage by UBS with a Buy rating and a specific price target of $27 suggests a positive sentiment from a reputable financial institution. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100